2026 ACTRIMS forum Kenneth P Johnson lecture. Autologous hematopoietic stem cell transplantation in multiple sclerosis and other neuroinflammatory conditions: Current evidence and remaining questions
Autologous hematopoietic stem cell transplantation has emerged as a highly effective treatment strategy for selected patients with active relapsing multiple sclerosis and is now being investigated in other neuroinflammatory diseases, including neuromyelitis optica spectrum disorder and stiff person syndrome, among others. Accumulating evidence from observational studies and clinical trials demonstrated sustained suppression of inflammatory disease activity in multiple sclerosis, whereas evidence in other neuroinflammatory diseases remains largely limited to case series. Major professional bodies have endorsed autologous hematopoietic stem cell transplantation as an option for active multiple sclerosis refractory to high-efficacy disease-modifying therapies. Nevertheless, even within the multiple sclerosis field, critical questions remain unresolved. The optimal conditioning regimen and benefit of CD34+ cell selection have not been established. Patient selection criteria require further refinement. Where to place autologous hematopoietic stem cell transplantation among current treatment options remains uncertain. Ongoing randomized trials are expected to substantially advance the evidence base.
Authors
- Amy C. Kunchok (ORCID: https://orcid.org/0000-0002-8387-6491)
- Jeffrey Allen Cohen (ORCID: https://orcid.org/0000-0001-9245-9772)
- Saira Afzal (ORCID: https://orcid.org/0000-0001-5893-7531)
Institutions
- Cleveland Clinic (US)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1177/13524585261502923
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00